![Caroline Stout](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Caroline Stout
Directeur en chef des Investissements chez
PANACEA ACQUISITION CORP. II
Profil
Ms. Caroline C.
Stout is an Independent Director at Affinia Therapeutics, Inc., a Chief Investment Officer at Panacea Acquisition Corp.
II and a Partner at EcoR1 Capital, LLC.
She is on the Board of Directors at Affinia Therapeutics, Inc. and Neogene Therapeutics, Inc. Ms. Stout joined EcoR1 in 2014 and has led several of the firm’s investments in the biotechnology sector.
She has also served as Chief Investment Officer of Panacea Acquisition Corp I and II.
Prior to joining EcoR1, Ms. Stout worked as an investment banker at Credit Suisse in New York.
Ms. Stout graduated magna cum laude from Georgetown University with a Bachelor of Arts in Economics, a Pre-Medical concentration, and Cognitive Science minor.
Postes actifs de Caroline Stout
| Sociétés | Poste | Début |
|---|---|---|
| PANACEA ACQUISITION CORP. II | Directeur en chef des Investissements | 01/01/2021 |
EcoR1 Capital, LLC
 EcoR1 Capital, LLC Investment ManagersFinance EcoR1 invests (long and short) in securities, consisting principally, but not solely, of equity and equity-related securities that are issued by biotechnology companies globally. | Analyst-Equity | 01/01/2014 |
Neogene Therapeutics, Inc.
 Neogene Therapeutics, Inc. BiotechnologyHealth Technology Operates as biotechnology company that provides TCR therapies targeting neo-antigens in solid cancers | Directeur/Membre du Conseil | 06/10/2020 |
Affinia Therapeutics, Inc.
 Affinia Therapeutics, Inc. BiotechnologyHealth Technology Develops adeno-associated virus gene therapies | Directeur/Membre du Conseil | 01/04/2021 |
Anciens postes connus de Caroline Stout
| Sociétés | Poste | Fin |
|---|---|---|
Panacea Acquisition Corp.
 Panacea Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Directeur en chef des Investissements | - |
Formation de Caroline Stout
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
73
Relations au 1er degré
6
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Georgetown University
 Georgetown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
EcoR1 Capital, LLC
EcoR1 Capital, LLC Investment ManagersFinance EcoR1 invests (long and short) in securities, consisting principally, but not solely, of equity and equity-related securities that are issued by biotechnology companies globally. | Finance |
Neogene Therapeutics, Inc.
Neogene Therapeutics, Inc. BiotechnologyHealth Technology Operates as biotechnology company that provides TCR therapies targeting neo-antigens in solid cancers | Health Technology |
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Develops adeno-associated virus gene therapies | Health Technology |
Panacea Acquisition Corp.
Panacea Acquisition Corp. Financial ConglomeratesFinance Operates as a blank check company | Finance |
Panacea Acquisition Corp. II
 Panacea Acquisition Corp. II Financial ConglomeratesFinance Operates as a blank check company | Finance |
